Business
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation
Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM)
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE CITY, March 18, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced the enrollment of the first patient in its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioavailable small molecule for the treatment of CCM.\n\n \n \n \n \n \n \n\n \n\"This is a big day for Recursion and the patients we hope to serve, as we announce the enrollment of the first patient in the first human efficacy trial in the company's history,\" said Recursion Co-Founder & CEO Chris Gibson, Ph.D. \"I have had the opportunity to get to know and work with many patients with CCM. It is a disease with incredible unmet need, affecting hundreds of thousands of people around the world and sometimes multiple generations within the same family. I am proud of the work of our team and thankful for the input from our friends and colleagues in the patient community who have enabled this critical milestone.\"\n\"Angioma Alliance families have long awaited the opportunity to participate in this first industry-sponsored clinical trial to treat cerebral cavernous malformations,\" said Angioma Alliance President and CEO Connie Lee, Psy.D. \"The SYCAMORE study represents a step forward into a new era; one in which our loved ones may face fewer brain surgeries and less disability. We appreciate Recursion's steadfast commitment to our patients.\" \n\"Historically, cavernomas have been managed primarily with observation, surgical resection, and occasionally radiotherapy. However, for a number of reasons, many patients with cavernomas must endure a life with neurologic symptoms,\" said Ryan Kellogg, MD, Investigator at the University of Virginia. \"This group of patients has long needed a new modality of treatment, and the opening of the SYCAMORE study, the first industry-sponsored study in the field, is an important step toward potential treatment options to reduce or eliminate the burden of this neurological disease.\"\nThe Phase 2 trial is designed as...